BOSTON--(BUSINESS WIRE)--Flex Pharma, Inc. (NASDAQ: FLKS), a biotechnology company that is developing innovative and proprietary treatments for nocturnal leg cramps and spasms associated with severe neuromuscular conditions, today announced the closing of its initial public offering of 5,400,000 shares of common stock at a public offering price of $16.00 per share, resulting in gross proceeds of $86.4 million, before underwriting discounts and commissions. All of the shares in the offering were sold by Flex Pharma. The company’s shares began trading on The NASDAQ Global Market on Thursday, January 29, 2015 under the ticker symbol “FLKS.”
Jefferies LLC and Piper Jaffray & Co. acted as joint book-running managers. JMP Securities LLC acted as lead manager and Cantor Fitzgerald & Co. and Roth Capital Partners, LLC acted as co-managers for the offering.
A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on January 28, 2015. This offering was made only by means of a prospectus. Copies of the final prospectus relating to this offering may be obtained by contacting: Jefferies LLC, Attn: Equity Syndicate Prospectus Department, 520 Madison Ave, 2nd Floor, New York, NY 10022, by telephone at (877) 547-6340 or by email at Prospectus_Department@Jefferies.com; or Piper Jaffray & Co., Attention: Equity Capital Markets, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, or by telephone at 800-747-3924 or by email at prospectus@pjc.com.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities, in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Flex Pharma
Flex Pharma, Inc. is a biotechnology company that is developing innovative and proprietary treatments for nocturnal leg cramps and spasms associated with severe neuromuscular conditions. In three randomized, blinded, placebo-controlled, cross-over studies, Flex Pharma’s proprietary treatment has shown a statistically significant reduction in the intensity of muscle cramps in healthy normal volunteers. In the second quarter of 2015, the Company intends to initiate at least one human proof-of-concept study of its proprietary treatment for individuals with nocturnal leg cramps.
Flex Pharma was founded by National Academy of Science members Rod MacKinnon, M.D. (2003 Nobel Laureate), and Bruce Bean, Ph.D., recognized leaders in the fields of ion channels and neurobiology, along with Chairman and Chief Executive Officer Christoph Westphal, M.D., Ph.D.
Contacts
Flex Pharma, Inc.
Elizabeth Woo, 617-874-1829
VP, Investor Relations & Corporate Communications
irdept@flex-pharma.com
Help employers find you! Check out all the jobs and post your resume.
